UTI vs XXI
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
UTI · Universal Technical Institute$19.93 ▲ 1.22%
XXI · Twenty One Capital$5.48 ▲ 2.62%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- UTI -32.8%
- XXI -65.8%
Head to head
| Metric | UTI | XXI |
|---|---|---|
| Price | $19.93 | $5.48 |
| Change today | ▲ 1.22% | ▲ 2.62% |
| Market cap | $1.10B | $1.90B |
| Return, 3 months | -25.4% | +19.7% |
| Return, year to date | -23.7% | -37.4% |
| Return, 1 year | -29.6% | -63.9% |
| P/E (TTM) | 32.7 | -20.3 |
| P/B | 3.2 | 0.9 |
| P/E percentile vs own 5y | 56th | 71st |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +7.2% | – |
| Net profit growth (YoY) | -78.6% | -101,411.4% |
| Gross margin | 48.1% | – |
| Operating margin | 5.0% | – |
| Net margin | 3.9% | – |
| Return on equity | 10.5% | – |
| Analyst target vs. price | +81.5% | – |
| Analyst buy share | 86% | – |
| RSI (14) | 41 | 44 |
| 30-day volatility | 57.4% | 56.0% |
| Max drawdown, 1 year | -63.9% | -79.2% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | – |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- XXI is the largest of the group by market value.
- UTI has returned the most over the past year.
- XXI carries the lowest trailing P/E.
- XXI has been the calmest stock over the last 30 days.